TrialAnnals of surgery2018

Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial.

Talar Tatarian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.